[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-incontinence-following-surgical-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-incontinence-following-surgical-procedure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,56],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100638434","phase-2-multimodal-prehabilitation-and-rehabilitation-for-men-undergoing-robot-assisted-radical-prostatectomy-100638434",false,"NCT07576335","Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy","Multimodal Perioperative Optimisation for Patients Undergoing Robot-Assisted Radical Prostatectomy: A Randomised Controlled Trial Targeting Postoperative Erectile Dysfunction (ROBOPREP Trial)","ROBOPREP","Inclusion Criteria:\n\n1. Adults aged ≥18 years undergoing elective robot-assisted radical prostatectomy (RARP) with curative intent for confirmed prostate cancer.\n2. Consulting a urological surgeon with an appointment at participating sites at least 4 weeks prior to scheduled surgery.\n3. Willingness to engage in prescribed self-directed interventions.\n\nExclusion Criteria:\n\n1. Cognitive impairment such that they lack capacity to provide informed consent.\n2. Currently taking intracavernosal injection therapy.\n3. Severe or complete erectile dysfunction at baseline, defined as an IIEF-5 score ≤7 or self-reported absence of erectile function.\n4. Prescribed nitrates or guanylate cyclase stimulators (e.g., riociguat) - pharmacological contraindication to PDE5 inhibitor use.\n5. Impaired renal function (GFR \\\u003C50 mL\u002Fmin and\u002For creatinine clearance \\\u003C30 mL\u002Fmin).\n6. Severe hepatic impairment or concurrent prescription of medications that inhibit CYP3A4.\n7. Loss of vision in one eye due to non-arteritic anterior ischaemic optic neuropathy (NAION).\n8. Myocardial infarction within the last 90 days.\n9. Stroke within the last 6 months.\n10. Unstable angina or angina occurring during sexual intercourse.\n11. New York Heart Association (NYHA) Class II or greater heart failure in the last 6 months.\n12. Uncontrolled arrhythmias, hypotension (\\\u003C90\u002F50 mmHg), or uncontrolled hypertension.\n13. Contraindications to participating in the prescribed exercise program.\n14. No access to a device with internet connectivity.","MALE","18 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Prostate cancer is the most common cancer in Australian men. Robot-assisted radical prostatectomy (RARP) - surgical removal of the prostate - is a standard treatment, but it frequently causes erectile dysfunction (ED) and urinary incontinence that can persist for years and significantly affect quality of life.\n\nThis trial (ROBOPREP) will test whether a multimodal program of prehabilitation (before surgery) and rehabilitation (after surgery) improves erectile function and urinary continence in men undergoing RARP, compared to standard care alone.\n\nThe program includes four components, all delivered virtually and in a self-directed manner:\n\n1. Pharmacological - tadalafil 5 mg once daily (a low-dose, TGA-approved erectile medication) beginning 4 weeks before surgery, paused during hospital admission, and resumed for 3 months following catheter removal after surgery.\n2. Exercise - pelvic floor muscle training (3 sets per day) and aerobic exercise (40 minutes, 4 times per week) to strengthen the muscles and vascular supply involved in erectile and urinary function.\n3. Nutrition - dietary guidance to support surgical recovery and vascular health.\n4. Psychological\u002Fwellbeing - relaxation techniques, psychoeducation about expected recovery, and self-compassion strategies to address cancer-related anxiety.\n\nA total of 64 men will be recruited across three major Sydney hospitals (Royal Prince Alfred Hospital, Concord Repatriation General Hospital, and Chris O'Brien Lifehouse) and randomly assigned 1:1 to the multimodal program plus standard care, or to standard care alone. Outcomes - including erectile function (primary), urinary continence, quality of life, and psychological wellbeing - are assessed at baseline and at 6 weeks, 3, 6, and 12 months following surgery. All participant-facing elements of the program are digital, low-cost, and designed for real-world scalability.",[27,28,29],"Erectile Dysfunction Following Radical Prostatectomy","Prostate Cancer","Urinary Incontinence Following Surgical Procedure",[31,32,33,34,35,36,37,38,39,40,41,42],"robot-assisted radical prostatectomy","prehabilitation","rehabilitation","erectile dysfunction","urinary incontinence","PDE5 inhibitor","tadalafil","pelvic floor muscle training","prostate cancer","sexual rehabilitation","perioperative care","multimodal intervention","NOT_YET_RECRUITING","2026-05-04",{"date":46,"type":47},"2026-05-08","ACTUAL",{"date":49,"type":21},"2026-05-01",{"date":51,"type":21},"2028-11-01",{"name":53,"class":54},"Surgical Outcomes Research Centre (SOuRCe)","NETWORK",3,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":67,"briefSummary":69,"conditions":70,"keywords":77,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100626004","predictors-of-trifecta-achievement-after-holep-100626004","NCT07429994","Predictors of Trifecta Achievement After HoLEP","Predictors of Trifecta Achievement After Holmium Laser Enucleation of the Prostate","ReMIUS-BPO","Inclusion Criteria:\n\n* All male patients aged ≥ 40 years who are candidates for surgical treatment for BPO.\n* Ability to provide informed consent, when required.\n\nExclusion Criteria:\n\n* Clinically proven active condition(s) that require another intervention other than BPO surgery, such as lower urinary tract malignancy, urethral stricture, or neurogenic lower urinary tract symptoms.\n* History of previous surgery for BPO, urethral stricture, or prostate cancer.\n* Incomplete baseline or procedural data.","40 Years",{"count":66,"type":21},604,[68],"NA","Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for men experiencing bothersome lower urinary tract symptoms due to an enlarged prostate. Researchers predict that specific participant or operator-dependent conditions before or during HoLEP may influence the trifecta outcome, based on similar studies. Therefore, the aim of this study is to understand what these conditions are. Trifecta success indicates a high-quality surgery based on three essential criteria: the treatment's effectiveness, ease of recovery, and the absence of serious side effects. In this study, trifecta is defined as relief from bothersome symptoms validated by international symptom score questionnaires, no urinary incontinence, and no serious events occurring within three months after HoLEP.",[71,72,29,73,74,75,76],"HoLEP","Trifecta Achievement","Clavien Dindo Surgical Complication Scale","Lower Urinary Tract Symptoms (LUTS)","Benign Prostatic Enlargement (BPE)","Bladder Outlet Obstruction",[78,79,80],"HoLEP Trifecta","HoLEP Symptomatic Relief","HoLEP Predictive Factors","2026-02-18",{"date":83,"type":47},"2026-02-24",{"date":85,"type":21},"2026-01-30",{"date":87,"type":21},"2028-07-31",{"name":89,"class":90},"Ondokuz Mayıs University","OTHER",1]